1 |
Kirschmann DA, Seftor EA, Hardy KM, Seftor RE and Hendrix MJ (2012) Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 18, 2726-2732
DOI
|
2 |
Cao Z, Bao M, Miele L, Sarkar FH, Wang Z and Zhou Q (2013) Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer 49, 3914-3923
DOI
|
3 |
Wagenblast E, Soto M, Gutierrez-Angel S et al (2015) A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature 520, 358-362
DOI
|
4 |
Hendrix MJ, Seftor EA, Hess AR and Seftor RE (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3, 411-421
DOI
|
5 |
Williamson SC, Metcalf RL, Trapani F et al (2016) Vascu logenic mimicry in small cell lung cancer. Nat Commun 7, 13322
DOI
|
6 |
Bharti R, Dey G and Mandal M (2016) Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement. Cancer Lett 375, 51-61
DOI
|
7 |
Dijkgraaf EM, Welters MJ, Nortier JW, van der Burg SH and Kroep JR (2012) Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des 18, 3816-3827
DOI
|
8 |
Rossi JF, Lu ZY, Jourdan M and Klein B (2015) Interleukin-6 as a therapeutic target. Clin Cancer Res 21, 1248-1257
DOI
|
9 |
Wang Y, Niu XL, Qu Y et al (2010) Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 295, 110-123
DOI
|
10 |
Hong L, Sharp T, Khorsand B et al (2016) MicroRNA-200c Represses IL-6, IL-8, and CCL-5 Expression and Enhances Osteogenic Differentiation. PLoS One 11, e0160915
DOI
|
11 |
Chen SC, Chang YL, Wang DL and Cheng JJ (2006) Herbal remedy magnolol suppresses IL-6-induced STAT3 activation and gene expression in endothelial cells. Br J Pharmacol 148, 226-232
DOI
|
12 |
Zhang W, Shen X, Xie L, Chu M and Ma Y (2015) Micro-RNA-181b regulates endotoxin tolerance by targeting IL-6 in macrophage RAW264.7 cells. J Inflamm (Lond) 12, 18
DOI
|
13 |
Hunter CA and Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16, 448-457
DOI
|
14 |
Kanda T and Takahashi T (2004) Interleukin-6 and cardiovascular diseases. Jpn Heart J 45, 183-193
DOI
|
15 |
Zhang GJ and Adachi I (1999) Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19, 1427-1432
|
16 |
Nakashima J, Tachibana M, Horiguchi Y et al (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6, 2702-2706
|
17 |
Seymour JF, Talpaz M, Cabanillas F, Wetzler M and Kurzrock R (1995) Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 13, 575-582
DOI
|
18 |
Jansson MD and Lund AH (2012) MicroRNA and cancer. Mol Oncol 6, 590-610
DOI
|
19 |
Lee A, McLean D, Choi J, Kang H, Chang W and Kim J (2014) Therapeutic implications of microRNAs in pulmonary arterial hypertension. BMB Rep 47, 311-317
DOI
|
20 |
Kim J (2018) MicroRNAs as critical regulators of the endothelial to mesenchymal transition in vascular biology. BMB Rep 51, 65-72
DOI
|
21 |
Kang H, Park Y, Lee A et al (2017) Negative regulation of NOD1 mediated angiogenesis by PPARgamma-regulated miR-125a. Biochem Biophys Res Commun 482, 28-34
DOI
|
22 |
Zhu WY, Luo B, An JY et al (2014) Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer. Cancer Invest 32, 394-401
DOI
|
23 |
Li Z, Pan W, Shen Y et al (2018) IGF1/IGF1R and micro- RNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells. Cell Cycle 17, 1212-1219
DOI
|
24 |
Shan Y, Liu Y, Zhao L, Liu B, Li Y and Jia L (2017) MicroRNA-33a and let-7e inhibit human colorectal cancer progression by targeting ST8SIA1. Int J Biochem Cell Biol 90, 48-58
DOI
|
25 |
Xiao M, Cai J, Cai L et al (2017) Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. J Ovarian Res 10, 24
DOI
|
26 |
Huang P, Mao LF, Zhang ZP et al (2018) Down-Regulated miR-125a-5p Promotes the Reprogramming of Glucose Metabolism and Cell Malignancy by Increasing Levels of CD147 in Thyroid Cancer. Thyroid 28, 613-623
DOI
|
27 |
Sun M, Guo S, Yao J et al (2019) MicroRNA-125a suppresses cell migration, invasion, and regulates hyaluronic acid synthase 1 expression by targeting signal transducers and activators of transcription 3 in renal cell carcinoma cells. J Cell Biochem 120, 1894-1902
DOI
|
28 |
Naidu S, Shi L, Magee P et al (2017) PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways. Sci Rep 7, 15441
DOI
|
29 |
Lu G, Ma Y, Jia C et al (2017) Reduced miR-125a levels associated with poor survival of patients with hepatocellular cancer. Oncol Lett 14, 5952-5958
|
30 |
McCall MN, Kent OA, Yu J, Fox-Talbot K, Zaiman AL and Halushka MK (2011) MicroRNA profiling of diverse endothelial cell types. BMC Med Genomics 4, 78
DOI
|
31 |
Zhou W, Fong MY, Min Y et al (2014) Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25, 501-515
DOI
|
32 |
Zhang Y, Zhang Q, Gui L et al (2018) Let-7e inhibits TNF-alpha expression by targeting the methyl transferase EZH2 in DENV2-infected THP-1 cells. J Cell Physiol 233, 8605-8616
DOI
|
33 |
Schnegg CI, Yang MH, Ghosh SK and Hsu MY (2015) Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma. Cancer Res 75, 1682-1690
DOI
|
34 |
van der Schaft DW, Seftor RE, Seftor EA et al (2004) Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 96, 1473-1477
DOI
|
35 |
Abdullah LN and Chow EK (2013) Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2, 3
DOI
|
36 |
Holen KD and Saltz LB (2001) New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. Lancet Oncol 2, 290-297
DOI
|
37 |
O'Reilly EA, Gubbins L, Sharma S et al (2015) The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin 3, 257-275
DOI
|
38 |
Bleau AM, Hambardzumyan D, Ozawa T et al (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226-235
DOI
|
39 |
Deanfield JE, Halcox JP and Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115, 1285-1295
DOI
|
40 |
Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100, 57-70
DOI
|
41 |
Lee A, Papangeli I, Park Y et al (2017) A PPARgammadependent miR-424/503-CD40 axis regulates inflammation mediated angiogenesis. Sci Rep 7, 2528
DOI
|
42 |
Jo HN, Kang H, Lee A et al (2017) Endothelial miR-26a regulates VEGF-Nogo-B receptor-mediated angiogenesis. BMB Rep 50, 384-389
DOI
|
43 |
Butler JM, Kobayashi H and Rafii S (2010) Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10, 138-146
DOI
|
44 |
Gilbert LA and Hemann MT (2010) DNA damage-mediated induction of a chemoresistant niche. Cell 143, 355-366
DOI
|
45 |
Folberg R and Maniotis AJ (2004) Vasculogenic mimicry. APMIS 112, 508-525
DOI
|